CAH · 10-Q · 2026Q3 · Full report

Pharmaceutical Specialty Demand

CARDINAL HEALTH INC · 2026-11-05 · Importance 49 · Surprise 32

Cardinal Health’s Pharma segment revenue increased 6% year over year to $62.6 billion, primarily from branded and specialty pharmaceutical sales growth with existing customers. The company also experienced increased demand for GLP-1 medications during the quarter, which contributed to Pharma and consolidated revenue growth but did not meaningfully contribute to segment profit. Management said GLP-1 demand growth had begun to moderate in fiscal 2026 and expects further moderation, while noting that demand remains unpredictable.

Key facts

• GLP-1 demand growth began moderating in fiscal 2026, and Cardinal Health expects further moderation in future demand growth; demand remains unpredictable. source
• Cardinal Health experienced increased GLP-1 medication demand during the three months ended September 30, 2026, positively affecting Pharma and consolidated revenue, but increased GLP-1 sales did not meaningfully contribute to segment profit. source